ALBO stock forecast
Our latest prediction for Albireo Pharma, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 25.14$.
In the short term (2weeks), ALBO's stock price should underperform the market by -2.94%. During that period the price should oscillate between -10.60% and +10.18%.
In the medium term (3months), ALBO's stock price should underperform the market by -7.83%. During that period the price should oscillate between -39.87% and +25.49%.
Get email alertsCreate a solid portfolio with ALBO
About Albireo Pharma, Inc.
Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
At the moment the company generates 11M USD in revenues.
On its last earning announcement, the company reported a loss of -5.88$ per share.
The book value per share is 12.49$
Three months stock forecastJuly 10, 2020
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11M | - | -75M | -709.50% | -78M | -5.88 | - | - | 13M | 12.49 | -63M | -1M | -64M |